Opportunity radar
4,186,134 patents indexed · 165,974,948 citations · issued 2005-01-04 → 2026-05-05
Showing50 of 25,005
Pharma (A61K)Therapy methods (A61P)Med devices (A61M)Agriculture (A01)Hand tools (B25)Consumer (A47)Energy (H01M)AI / ML (G06N)
| Patent # | Title | Assets | Issued | Expires | Fwd cites | Score |
|---|---|---|---|---|---|---|
| 12540166 | BNIP3 peptides for treatment of reperfusion injury | 🖼🧊📄§ | 2026-02-03 | 2040-05-08 | 0 | 31 |
| 12540197 | Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates | 🖼🧊📄§ | 2026-02-03 | 2044-10-11 | 0 | 31 |
| 12539329 | Treatment regimen for the treatment of autoimmune disorders | 🖼🧊📄§ | 2026-02-03 | 2044-03-08 | 0 | 31 |
| 12539297 | Composition for inhibiting cancer metastasis and treating cancer | 🖼🧊📄§ | 2026-02-03 | 2042-05-11 | 0 | 31 |
| RE050776 | Inhibitors of cyclin-dependent kinases | 🖼🧊📄§ | 2026-02-03 | 2043-03-09 | 0 | 31 |
| 12540139 | Imidazopiperazine inhibitors of transcription activating proteins | 🖼🧊📄§ | 2026-02-03 | 2043-03-13 | 0 | 31 |
| 12540115 | Inhibitors of phospholipid synthesis and methods of use | 🖼🧊📄§ | 2026-02-03 | 2040-08-20 | 0 | 31 |
| 12540191 | Engineered immune cells targeting BCMA and their uses thereof | 🖼🧊📄§ | 2026-02-03 | 2043-09-29 | 0 | 31 |
| 12540143 | Methods and compositions for targeted protein degradation | 🖼🧊📄§ | 2026-02-03 | 2040-04-08 | 0 | 31 |
| 12539322 | Use of mulberry extract for controlling postprandial glucose response | 🖼🧊📄§ | 2026-02-03 | 2041-04-23 | 0 | 31 |
| 12540167 | Cytokine combination | 🖼🧊📄§ | 2026-02-03 | 2042-11-17 | 0 | 31 |
| 12540174 | Kits and containers for treating vimentin expressing tumors | 🖼🧊📄§ | 2026-02-03 | 2042-10-07 | 0 | 31 |
| 12539319 | Lactobacillus delbrueckii subsp. lactis CKDB001 strain, and composition for prevention, amelioration, or treatment of non-alcoholic fatty liver comprising same | 🖼🧊📄§ | 2026-02-03 | 2041-03-23 | 0 | 31 |
| 12539285 | Therapeutic agent for hypertrophic cardiomyopathy | 🖼🧊📄§ | 2026-02-03 | 2042-01-24 | 0 | 31 |
| 12539287 | L-DOPA microbiome therapy | 🖼🧊📄§ | 2026-02-03 | 2043-01-12 | 0 | 31 |
| 12540175 | Anti-ApoE antibodies | 🖼🧊📄§ | 2026-02-03 | 2044-02-08 | 0 | 31 |
| 12540335 | Compositions and methods for the treatment of metabolic liver disorders | 🖼🧊📄§ | 2026-02-03 | 2041-03-04 | 0 | 31 |
| 12533379 | Application of TREM2hi macrophages in the preparation of drugs for the treatment of cardiac dysfunction | 🖼🧊📄§ | 2026-01-27 | 2042-11-06 | 0 | 31 |
| 12533309 | Minoxidil adjuvant therapies | 🖼🧊📄§ | 2026-01-27 | 2042-06-10 | 0 | 31 |
| 12533361 | Use of polaprezinc in preparing drug for treating castration-resistant prostate cancer | 🖼🧊📄§ | 2026-01-27 | 2042-06-01 | 0 | 31 |
| 12533334 | Compositions and methods for modulating equine fatty acid profiles | 🖼🧊📄§ | 2026-01-27 | 2044-06-17 | 0 | 31 |
| 12534435 | Lipids and nanoparticle compositions thereof | 🖼🧊📄§ | 2026-01-27 | 2041-03-26 | 0 | 31 |
| 12535491 | Vaccine comprising protein-targeted (PT) extracellular DNA isolated from bacterial matrix | 🖼🧊📄§ | 2026-01-27 | 2039-04-08 | 0 | 31 |
| 12533386 | Preparation of black tea extract with high theaflavin content and use thereof | 🖼🧊📄§ | 2026-01-27 | 2042-11-06 | 0 | 31 |
| 12533409 | Compositions and methods for targeting mutant RAS | 🖼🧊📄§ | 2026-01-27 | 2040-01-24 | 0 | 31 |
| 12533374 | Compositions and methods of use thereof | 🖼🧊📄§ | 2026-01-27 | 2041-04-30 | 0 | 31 |
| 12533427 | Radioactive antitumor agent | 🖼🧊📄§ | 2026-01-27 | 2038-10-26 | 0 | 31 |
| 12533353 | Methods of treatment of cancer comprising CDC7 inhibitors | 🖼🧊📄§ | 2026-01-27 | 2039-08-28 | 0 | 31 |
| 12534762 | Treating atopic dermatitis by targeting the WNT pathway | 🖼🧊📄§ | 2026-01-27 | 2039-09-27 | 0 | 31 |
| 12533333 | Method of treatment of obesity | 🖼🧊📄§ | 2026-01-27 | 2044-05-29 | 0 | 31 |
| 12534540 | CYP1A1-targeted monoclonal antibody with reactivity across vertebrate taxa | 🖼🧊📄§ | 2026-01-27 | 2044-01-23 | 0 | 31 |
| 12533399 | Composition comprising tTF-NGR for use in treating soft-tissue sarcoma | 🖼🧊📄§ | 2026-01-27 | 2041-08-23 | 0 | 31 |
| 12534535 | Monoclonal antibody or antibody fragment against canine CD20 | 🖼🧊📄§ | 2026-01-27 | 2040-10-02 | 0 | 31 |
| 12533359 | Method for preventing hair loss | 🖼🧊📄§ | 2026-01-27 | 2040-07-02 | 0 | 31 |
| 12534729 | Uses of synthetic lethal partners for treatment of cancer | 🖼🧊📄§ | 2026-01-27 | 2040-05-29 | 0 | 31 |
| 12533330 | (2S)-2-aminopentanethioic s-acid for use as medicament and in therapy of amyotrophic lateral sclerosis | 🖼🧊📄§ | 2026-01-27 | 2040-12-04 | 0 | 31 |
| 12534528 | Anti-LILRB1 antibody and uses thereof | 🖼🧊📄§ | 2026-01-27 | 2040-12-22 | 0 | 31 |
| 12533382 | Composite including neural retina, retinal pigment epithelial cells, and hydrogel, and method for producing same | 🖼🧊📄§ | 2026-01-27 | 2040-04-24 | 0 | 31 |
| 12534515 | Broadly neutralizing anti-HIV-1 antibodies and methods of use thereof | 🖼🧊📄§ | 2026-01-27 | 2043-12-20 | 0 | 31 |
| 12533425 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | 🖼🧊📄§ | 2026-01-27 | 2040-10-09 | 0 | 31 |
| 12534709 | Shaped organoid compositions and methods of making same | 🖼🧊📄§ | 2026-01-27 | 2040-05-29 | 0 | 31 |
| 12534541 | Anti-PTK7 antibody and uses thereof | 🖼🧊📄§ | 2026-01-27 | 2045-02-14 | 0 | 31 |
| 12534521 | Antibodies specifically recognizing C5A and uses thereof | 🖼🧊📄§ | 2026-01-27 | 2041-06-18 | 0 | 31 |
| 12534538 | Anti-HER2 binding molecules | 🖼🧊📄§ | 2026-01-27 | 2040-03-20 | 0 | 31 |
| 12533317 | Stem cell-derived exosomes containing pain regulators, and uses thereof | 🖼🧊📄§ | 2026-01-27 | 2041-04-07 | 0 | 31 |
| 12533364 | Methods and compositions for testosterone production | 🖼🧊📄§ | 2026-01-27 | 2045-05-30 | 0 | 31 |
| 12533343 | Method for preparing (−)-cibenzoline succinate | 🖼🧊📄§ | 2026-01-27 | 2039-09-20 | 0 | 31 |
| 12534520 | YKL-40-targeting human monoclonal antibody | 🖼🧊📄§ | 2026-01-27 | 2040-09-07 | 0 | 31 |
| 12533322 | Nanoparticle containing hydrophobic substance and manufacturing process and use thereof | 🖼🧊📄§ | 2026-01-27 | 2041-12-20 | 0 | 31 |
| 12534726 | Composition and method for inhibiting angiotensinogen (AGT) protein expression | 🖼🧊📄§ | 2026-01-27 | 2045-03-19 | 0 | 31 |